title: Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.
abstract: We conducted a prospective study to investigate the role of four single nucleotide polymorphisms (SNPs) of XPG on the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with platinum-based doublets chemotherapy. In total, 277 patients with histologically confirmed NSCLC were mainly from December 2007 and December 2008. The genotypes of rs2296147T>C, rs1047768C>T, rs873601G>A, and rs17655G>C were determined by polymerase chain reaction-restriction fragment length polymorphism. By univariate analysis, a shorter survival was associated with older age, sex, and higher disease stage. By multivariate Cox regression analysis, patients carrying rs2296147 TT genotype and T allele were prognostic factors of progression-free survival (PFS) and overall survival (OS). Similarly, patients carrying rs873601 GG genotype and G allele were marginally significantly associated with favorable outcome for PFS and OS. We found that individuals carrying both rs2296147 T allele and rs873601 G allele were associated with better PFS and OS. However, rs1047768C>T and rs17655G>C polymorphisms did not influence the PFS and OS of advanced NSCLC. In summary, our study provided statistical evidence that XPG rs2296147T>C and rs873601G>A polymorphisms may be used as surrogate markers toward individualizing NSCLC treatment strategies.
authors.affiliation: Department of Thoracic Surgery, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: Weicai
authors.initials: W
authors.lastname: Hu
authors.forename: Jinbing
authors.initials: J
authors.lastname: Pan
authors.forename: Pu
authors.initials: P
authors.lastname: Zhao
authors.forename: Guangyu
authors.initials: G
authors.lastname: Yang
authors.forename: Shujuan
authors.initials: S
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D004268:DNA-Binding Proteins / Q000235:genetics*; D004720:Endonucleases / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics*; D010984:Platinum / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D016016:Proportional Hazards Models; D014157:Transcription Factors / Q000235:genetics*; D016896:Treatment Outcome; D000099250:DNA Excision Repair Protein ERCC-5
chemical_list: D004268:DNA-Binding Proteins; D004720:Endonucleases; D009687:Nuclear Proteins; D010984:Platinum; D014157:Transcription Factors; D000099250:DNA Excision Repair Protein ERCC-5